UK paracetamol recalled amid contamination concerns

After reports of possible contamination, the UK’s health authorities have urgently recalled specific batches of paracetamol. The Medicines and Healthcare products Regulatory Agency, (MHRA), is moving quickly to ensure the safety of the public while investigations continue.

Recalling batch numbers

Two batches of Paracetamol tablets 500mg produced by Chelonia Healthcare Limited are affected. The batch numbers for the two batches are:

• 2312010 (expiry: 30 November 2027; first distributed on 14 April 2025).
• 2312011 (expiry: 31 November 2027; first distributed on 15 May 2025).

The only way to obtain these pots is by prescription.

Recall for a Reason

A recall was initiated after some healthcare professionals discovered discoloured tablets within certain containers. Batch 2312010 was the first batch to be affected, but now batch 2312011 will also be recalled until further analysis has been conducted. The discolouration raised fears of contamination. However, there have not been any confirmed reports that patients were harmed. Contaminated Paracetamol Tablets can cause health problems, particularly when taken in high doses or for a long period of time. Studies have shown that paracetamol use can lead to gastrointestinal, renal, and cardiovascular complications. This is especially true for older adults.

Guidelines for Patients and Health Professionals

Patients are encouraged to:

• The batch numbers on your paracetamol bottle may be affected.
• You can return any medications from these lots to your pharmacy.
• Consult your pharmacist or healthcare professional if you notice that any tablets are discolored or if you experience adverse reactions.

The healthcare professionals were instructed to stop immediately supplying the batches in question, quarantine and return any remaining stock to their supplier.

Ongoing Investigation

The MHRA, in conjunction with Chelonia Healthcare Limited, is investigating the source and extent of the contamination. Patients who experience any adverse reactions or have concerns about their medication are advised to seek medical attention and report any suspected reactions via the MHRA Yellow Card scheme.It’s important to pay attention to any medication you may have under the Chelonia Healthcare Ltd name.

This recall demonstrates the importance and urgency of regulatory agencies in responding to any potential health risk. We will continue to provide updates as the investigation proceeds.